BPA for adstiladrin
Active Awarded Last action
- Contract number
- 36E79724A0011
- Awardee
-
Ferring Pharmaceuticals Inc. UEI D6ATBE6Y96L5
- Awarding agency
-
National Acquisition Center
Headquarters, Department of Veterans Affairs
- Task orders
- 0
Award facts
- Opportunity
-
- VA797P12Q0002 Solicitation number
- Last date to order 87% complete
- IDV ceiling
- $5,957,790.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
Ferring Pharmaceuticals Inc. has been awarded a single-award Blanket Purchase Agreement valued at $5.96 million by the Department of Veterans Affairs' National Acquisition Center for the supply of Adstiladrin (nadofaragene firadenovec), a specialized immunotherapy treatment for non-muscle invasive bladder cancer. This BPA, awarded on March 15, 2024, and extending through March 14, 2027, operates under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and represents the exercise of an option year within the broader contracting vehicle (BPA 36E79724A0011). The contract is structured as a firm-fixed price agreement with no set-aside designation, establishing a dedicated procurement pathway for Adstiladrin supply to support veteran oncology care across Department of Veterans Affairs medical centers and integrated service networks nationwide. Ferring maintains operational fulfillment capacity from its facilities in Parsippany, New Jersey, and Carrollton, Texas, enabling geographic distribution to support geographically dispersed VA medical facilities.
Under this BPA, the Department of Veterans Affairs anticipates issuing delivery orders to procure Adstiladrin for administration to veterans requiring treatment for genitourinary and bladder cancers. Historical delivery order patterns through predecessor indefinite-delivery vehicles indicate individual orders ranging from approximately $45,000 to $275,000, with the VA's Veterans Integrated Service Networks (VISNs) placing orders on an as-needed basis to support patient treatment requirements. This contract provides a streamlined acquisition mechanism complementary to Ferring's existing multiple-award indefinite-delivery contract, allowing the VA to maintain reliable access to this specialized pharmaceutical product while supporting the agency's mission to deliver comprehensive oncology treatment options to the veteran population.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 36E79724A0011?
36E79724A0011 was awarded to Ferring Pharmaceuticals Inc. by National Acquisition Center (Headquarters) on March 15, 2024.
How much is contract 36E79724A0011 worth?
36E79724A0011's own ceiling is $5,957,790.
Who can order from contract 36E79724A0011?
36E79724A0011 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.
Is contract 36E79724A0011 under another contract?
Yes. 36E79724A0011 is a blanket purchase agreement under 36F79720D0136, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36E79724A0011 competed?
The extent of competition for 36E79724A0011 was full and open competition. The government received 1 offer.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV